Dank Gillian, Rassnick Kenneth M, Kristal Orna, Rodriguez Carlos O, Clifford Craig A, Ward Rebecca, Mallett Courtney L, Gieger Tracy, Segev Gilad
School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot 76100, Israel.
J Am Vet Med Assoc. 2011 Oct 1;239(7):966-71. doi: 10.2460/javma.239.7.966.
OBJECTIVE-To determine outcome of dogs with presumed primary hepatic lymphoma treated with various multiagent, doxorubicin-based chemotherapeutic protocols and identify factors associated with prognosis. DESIGN-Retrospective case series. ANIMALS-18 dogs with presumed primary hepatic lymphoma. PROCEDURES-Medical records were reviewed for information on signalment, treatment, and outcome. RESULTS-8 dogs had a complete remission (CR), with a median remission duration of 120 days. Dogs with leukocytosis, neutrophilia, hypoalbuminemia, hyperbilirubinemia, or a combination of hypoalbuminemia and hyperbilirubinemia were less likely to achieve a CR. Overall median survival time (MST) was 63 days (range, 2 to 402 days). In a multivariate analysis, response to treatment and serum albumin concentration were associated with MST. Dogs that did not achieve a CR had a significantly shorter MST than did dogs that did achieve a CR (13 vs 283 days, respectively). Dogs with serum albumin concentration < 2.5 g/dL at the time treatment was initiated had a significantly shorter MST than did dogs with serum albumin concentration within reference limits (10 vs 128 days, respectively). There was also a positive correlation between serum albumin concentration and survival time (r = 0.74). CONCLUSIONS AND CLINICAL RELEVANCE-Results suggested that dogs with primary hepatic lymphoma that underwent chemotherapy had a poor prognosis, with a low response rate. Dogs that responded to treatment had a better prognosis, and dogs with hypoalbuminemia had a poorer prognosis.
目的——确定采用各种基于多柔比星的多药化疗方案治疗的疑似原发性肝淋巴瘤犬的预后，并确定与预后相关的因素。设计——回顾性病例系列。动物——18只疑似原发性肝淋巴瘤犬。程序——查阅病历以获取有关信号、治疗和预后的信息。结果——8只犬完全缓解（CR），缓解持续时间中位数为120天。患有白细胞增多、中性粒细胞增多、低白蛋白血症、高胆红素血症或低白蛋白血症和高胆红素血症组合的犬达到CR的可能性较小。总体中位生存时间（MST）为63天（范围为2至402天）。在多变量分析中，治疗反应和血清白蛋白浓度与MST相关。未达到CR的犬的MST明显短于达到CR的犬（分别为13天和283天）。治疗开始时血清白蛋白浓度<2.5 g/dL的犬的MST明显短于血清白蛋白浓度在参考范围内的犬（分别为10天和128天）。血清白蛋白浓度与生存时间之间也存在正相关（r = 0.74）。结论和临床意义——结果表明，接受化疗的原发性肝淋巴瘤犬预后较差，缓解率较低。对治疗有反应的犬预后较好，低白蛋白血症犬预后较差。
